Piperacillin and Tazobactam Injection IP

PIPZACT-4.5 is a potent, broad-spectrum intravenous antibiotic formulation by Pacitora Biotech containing Piperacillin (a ureidopenicillin) and Tazobactam (a beta-lactamase inhibitor) in a 4.5 gm vial. This powerful combination is indicated for the treatment of moderate to severe bacterial infections, including hospital-acquired pneumonia, complicated intra-abdominal infections, complicated urinary tract infections, sepsis, neutropenic fever (empiric therapy) , skin and soft tissue infections, and gynecological infections.

Piperacillin alone is a broad-spectrum penicillin but is destroyed by beta-lactamase enzymes produced by resistant bacteria. Tazobactam inactivates these enzymes, “shielding” the piperacillin and extending its spectrum to include many resistant organisms. This combination is particularly valuable for its excellent activity against Pseudomonas aeruginosa – a challenging pathogen in hospitalized patients.

Key Benefits:

• Broad-Spectrum Coverage – Effective against Gram-positive, Gram-negative & anaerobic bacteria.

• Overcomes Antibiotic Resistance – Tazobactam protects piperacillin from beta-lactamase destruction.

• Excellent Pseudomonas Coverage – One of the few beta-lactams effective against Pseudomonas aeruginosa.

• Treats Severe Infections – Nosocomial pneumonia, complicated intra-abdominal infections, sepsis.

• Neutropenic Fever Empiric Therapy – Guidelines recommend piperacillin-tazobactam as monotherapy.

• Synergistic with Aminoglycosides – For severe or life-threatening infections.

• High Dosing (4.5 gm) – For moderate to severe infections requiring intensive therapy.

• Trusted Quality – Manufactured under strict pharmaceutical standards by Pacitora Biotech.

FAQs:

1. What is the advantage of Pipzact-4.5 over other broad-spectrum antibiotics?
Pipzact-4.5 offers excellent Pseudomonas coverage plus activity against anaerobes (including B. fragilis) – making it suitable as monotherapy for mixed infections like intra-abdominal sepsis and diabetic foot.

2. Is Pipzact-4.5 effective against MRSA?
No – Pipzact-4.5 does NOT cover MRSA. If MRSA is suspected, add vancomycin, linezolid, or another MRSA-active agent.

3. Do I need to adjust the dose for kidney disease?
Yes – dose adjustment is essential in renal impairment. For CrCl <40 mL/min, the dose and/or frequency must be reduced. Always follow your physician’s prescription.

4. What is the most common side effect of Pipzact-4.5?
Diarrhea is the most common side effect. Monitor for persistent or bloody diarrhea, which may indicate Clostridium difficile infection (requiring treatment).